Coronary artery disease (CAD) is the most prevalent form of heart disease, affecting approximately 18 million adults in the ...
News-Medical.Net on MSN
Evolocumab shows clear benefit in preventing first-time heart attacks and strokes
Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular ...
Dr. Han adds to this, saying, “The diets with the strongest evidence to lower cholesterol are the diets that recommend food ...
Strategies to identify and treat early atherosclerosis are urgently needed to reduce the risk of cardiovascular complications. A paper in Nature now reports that imidazole propionate (ImP), a molecule ...
News-Medical.Net on MSN
Exploring m6A RNA modification as a therapeutic target in cardiovascular disorders
Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of ...
Cleerly, a leader in AI-based cardiovascular imaging, presented new, late-breaking science from the international CONFIRM2 ...
MedPage Today on MSN
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback